四川科伦生物科技公布了 sacituzumab tirumotecan 治疗三阴性乳腺癌的 III 期结果，与化疗相比，无进展生存期和总生存期均有所改善。 Sichuan Kelun-Biotech presents promising Phase III results for sacituzumab tirumotecan in triple-negative breast cancer, with improved progression-free and overall survival compared to chemotherapy.

Sichuan Kelun-Biotech在最近的肿瘤学会议上介绍了其TROP2-ADC、sacituzumab tirumotecan(Sac-TMT)的有希望的成果。 Sichuan Kelun-Biotech presented promising results for its TROP2-ADC, sacituzumab tirumotecan (sac-TMT), at recent oncology conferences. 与化疗相比,第三期研究显示,sac- TMT显著改善了三阴性乳腺癌 (TNBC) 患者的无进展生存期 (6. 7个月) 和整体生存期. A Phase III study showed sac-TMT significantly improved progression-free survival (6.7 months) and overall survival in triple-negative breast cancer (TNBC) patients compared to chemotherapy. 第二阶段的研究表明,如果结合抗DPD-L1抗体,在先进的非小型细胞肺癌中具有潜力。 A Phase II study indicated its potential in advanced non-small-cell lung cancer when combined with an anti-PD-L1 antibody. Sac-TMT可能成为这些癌症的一种新的标准治疗选择。 Sac-TMT may become a new standard treatment option for these cancers.